Influenza group 1 hemagglutinin epitopes (Group 1 HA epitopes)

Influenza group 1 hemagglutinin (HA) epitopes are specific antigenic regions on the surface glycoprotein of Group 1 influenza A viruses, which include subtypes such as H1, H2, H5, and H9. Hemagglutinin is a class I fusion protein that mediates viral entry by binding to host cell sialic acid receptors and facilitating the fusion of the viral envelope with the endosomal membrane. While the globular head of HA is highly variable and prone to mutations (antigenic drift), the stem or stalk region contains highly conserved epitopes that are shared across diverse Group 1 subtypes. These conserved epitopes are critical targets for the development of universal influenza vaccines and broadly neutralizing monoclonal antibodies (bnAbs). Therapeutic agents targeting these epitopes typically function by preventing the conformational changes necessary for membrane fusion or by inhibiting the proteolytic activation of the HA protein, thereby neutralizing the virus across multiple strains. Clinical development in this area focuses on monoclonal antibodies like CR6261 and VIS410, as well as novel vaccine platforms designed to redirect the immune response toward these immunosubdominant sites.

Other names

Group 1 HA stem epitopesGroup 1 influenza A hemagglutininConserved HA epitopesInfluenza A group 1 HA stalkHA1/HA2 conserved regionsHemagglutinin group 1 epitopes

Inhibition of viral-host membrane fusion by stabilizing the pre-fusion conformation of the HA stem; blocking of the proteolytic cleavage of the HA0 precursor into HA1 and HA2 subunits; and prevention of viral attachment or egress through binding to conserved head or stem regions.